ClinicalTrials.gg
Not yet recruitingNCT07947225Updated Nov 18, 2026

Preoperative Venous Collapsibility Indices and Post-Induction Hypotension in Patients Undergoing Elective Isolated Coronary Artery Bypass Grafting

An observational study in Post-induction Hypotension (PIH), sponsored by Istanbul University - Cerrahpasa. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul University - Cerrahpasa · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
102
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine whether changes in the size of three large veins during normal breathing are associated with low blood pressure shortly after general anaesthesia begins in adults scheduled for planned coronary artery bypass surgery.

Before anaesthesia, a researcher will use ultrasound to measure how much the three veins narrow and widen as each participant breathes normally. The research team will then monitor blood pressure during the first 10 minutes after anaesthesia begins. The study hypothesis is that the amount of change in vein size is associated with the likelihood of low blood pressure during this period. The team will compare how well the three measurements distinguish between participants who develop low blood pressure and those who do not. The ultrasound results will not be used to guide anaesthesia or treatment.

Read the detailed description

This single-centre, prospective observational cohort study will be conducted at the Institute of Cardiology, Istanbul University-Cerrahpasa. Adults scheduled for elective isolated coronary artery bypass grafting will be enrolled consecutively.

A single investigator will perform all ultrasound examinations before any sedative or anaesthetic medication is administered. Participants will lie supine with the head in a neutral position and breathe quietly without assistance. The right internal jugular vein, right subclavian vein and inferior vena cava will be assessed in each participant. For each vein, the maximum and minimum internal anteroposterior diameters will be measured using M-mode ultrasound over three separate respiratory cycles. The collapsibility index for each cycle will be calculated by subtracting the minimum diameter from the maximum diameter, dividing the difference by the maximum diameter and multiplying by 100. The mean of the three cycle-specific indices will be used for each vein. The vein and the reason for any technically inadequate measurement will be recorded.

Invasive arterial pressure will be monitored continuously during the observation period. Baseline mean arterial pressure will be calculated as the average of three stable readings obtained one minute apart before any sedative or anaesthetic medication is administered. The start of intravenous fentanyl administration will mark the start of induction and the beginning of the 10-minute observation period. The anaesthetist performing induction will be unaware of the ultrasound results. The attending anaesthetist will determine perioperative management and treatment according to clinical judgement.

The association between each venous collapsibility index and post-induction hypotension will be assessed in a separate logistic regression model. Discrimination will be evaluated using the area under the receiver operating characteristic curve. The three areas will be compared using the paired DeLong test in participants with valid measurements for all three veins.

02

Conditions studied

  • Post-induction Hypotension (PIH)

Browse trials for

Keywords

  • venous collapsibility index
  • post-induction hypotension
  • Point-of-Care Ultrasound
  • Internal Jugular Vein
  • Subclavian Vein
  • Inferior Vena Cava
03

In context

Hypotension

889 studies on the registry are indexed under Hypotension; 197 are open to participants now.

This study's planned enrollment of 102 is above the median of 90 across 267 observational studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adults scheduled for elective isolated coronary artery bypass grafting at the Institute of Cardiology, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. Patients will be screened consecutively during the study period. Those who meet the eligibility criteria and provide written informed consent will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Scheduled for elective isolated coronary artery bypass grafting.
  • Provides written .

Exclusion criteria

Exclusion Criteria:

  • Urgent or emergency surgery.
  • Planned concomitant cardiac surgery in addition to coronary artery bypass grafting.
  • below 40% on preoperative transthoracic echocardiography.
  • Tricuspid annular plane systolic excursion (TAPSE) of 17 mm or less, or severe right ventricular systolic dysfunction on preoperative echocardiographic assessment.
  • Severe or greater tricuspid regurgitation.
  • Haemodynamic instability requiring vasopressor or inotropic support before induction of anaesthesia.
  • Known thrombosis in a vein selected for ultrasound assessment or an indwelling catheter that interferes with the planned measurement.
  • Inability to assume the position required for venous ultrasonography.
  • No reliable ultrasound measurements can be obtained from the three target veins during quiet spontaneous breathing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
102 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults Undergoing Elective Isolated Coronary Artery Bypass Grafting

    Adults scheduled for elective isolated coronary artery bypass grafting will undergo venous ultrasound before induction of general anaesthesia. Collapsibility indices will be measured in the right internal jugular vein, right subclavian vein and inferior vena cava during quiet spontaneous breathing. Participants will be observed for hypotension during the first 10 minutes after induction begins. The ultrasound findings will be used for research analysis.

    Diagnostic Test: Pre-induction Venous Ultrasonography

Interventions

  • Diagnostic testPre-induction Venous Ultrasonography

    Bedside M-mode ultrasonography will be performed before administration of any sedative or anaesthetic medication. The collapsibility index for each vein will be calculated from diameter changes during three quiet spontaneous respiratory cycles. The ultrasound findings will not be used to guide anaesthesia or treatment.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Post-Induction Hypotension

    Proportion of participants who experience at least one episode of hypotension during the first 10 minutes after induction of general anaesthesia begins. Hypotension is defined as a mean arterial pressure (MAP) below 65 mmHg or a decrease of more than 20% from baseline MAP. Baseline MAP is the mean of three stable invasive arterial pressure readings taken one minute apart before administration of any sedative or anaesthetic medication. Arterial pressure will be monitored continuously. After measurement artefacts have been excluded, any episode meeting either criterion will count, including episodes that resolve rapidly after treatment.

    Time frame: Within the first 10 minutes from the start of intravenous fentanyl administration for induction of general anaesthesia.

Secondary outcomes

  1. Lowest Mean Arterial Pressure

    Lowest artefact-free mean arterial pressure (MAP), in mmHg, recorded by continuous invasive arterial pressure monitoring during the observation period.

    Time frame: During the first 10 minutes after the start of intravenous fentanyl administration for induction of general anaesthesia.

  2. Maximum Absolute Decrease in Mean Arterial Pressure

    Baseline mean arterial pressure (MAP) minus the lowest artefact-free MAP recorded during the observation period, expressed in mmHg.

    Time frame: During the first 10 minutes after the start of intravenous fentanyl administration for induction of general anaesthesia.

  3. Maximum Percentage Decrease in Mean Arterial Pressure

    Baseline mean arterial pressure (MAP) minus the lowest artefact-free MAP recorded during the observation period, divided by baseline MAP and multiplied by 100.

    Time frame: During the first 10 minutes after the start of intravenous fentanyl administration for induction of general anaesthesia.

  4. Proportion of Participants Requiring Vasopressors for Hypotension

    Proportion of participants who receive at least one vasopressor dose to treat hypotension during the observation period. The agent, dose and administration time will be recorded for each administration.

    Time frame: During the first 10 minutes after the start of intravenous fentanyl administration for induction of general anaesthesia.

  5. Discrimination of Post-Induction Hypotension by Pre-Induction Venous Collapsibility Indices

    The area under the receiver operating characteristic curve (AUC) and its 95% confidence interval will be estimated for each pre-induction venous collapsibility index (internal jugular vein, subclavian vein and inferior vena cava) to assess discrimination of post-induction hypotension. AUCs will be compared using the paired DeLong test in participants with valid measurements for all three indices.

    Time frame: Venous indices measured before induction of general anaesthesia. Hypotension assessed within the first 10 minutes from the start of intravenous fentanyl administration for induction.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There is no current plan to share individual participant data with other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

Of 148 non-industry observational studies under Hypotension, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's planned 5 months is below that.

Counting every sponsor, half of 153 studies reached it within 11 months; a quarter within 5 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Dec 10, 2026
Primary completionEst.
May 10, 2027
CompletionEst.
Jun 10, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947225
Responsible party
Gozde Altun (assistant proffessor, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Nov 18, 2026
Start date
Dec 10, 2026 (estimated)
Primary completion
May 10, 2027 (estimated)
Completion
Jun 10, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Gozde Altun
Contact
gozde.altun@iuc.edu.tr
+905544290333

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion